Becton Dickinson said on Tuesday that it has acquired Cytognos, a privately held developer of flow cytometry-based tests for hematologic cancer and blood diseases, from its parent firm Vitros.

Medix Biochemica has acquired 100 percent of the shares of myPOLS Biotec GmbH, a German manufacturer of innovative and high-quality raw materials in molecular diagnostics.

Thermo Fisher Scientific on Wednesday morning reported a 1 percent increase in fourth quarter revenues and a 22 percent rise in full-year 2021 revenues. The company also raised its revenue and earnings guidance for 2022.

Two researchers from Skoltech and McGill University have published a review of the promising research field known as structural proteomics in the influential journal Chemical Reviews.

Danaher reported on Thursday a 21 percent year-over-year increase in total sales for the fourth quarter, beating the consensus Wall Street estimate. For the three months ended Dec. 31, conglomerate posted $8.15 billion in total sales compared to $6.76 billion in the year-ago period. The analysts' average estimate was $7.92 billion.

iHealth announced that it was disclosed in the previous announcement that the U.S. subsidiary of the company and the ACC of U.S. signed a purchase contract on ihealth coronavirus antigen home self-test OTC kit products on behalf of HHS, purchasing a total of 250 million iHealth kit products.

VIEW has been indexed in Chemical Abstracts Service (CAS) and Information Service for the Physics, Electro-technology, Computer and Control (INSPEC).

Abbott reported Wednesday morning that its fourth quarter diagnostics revenues rose 3 percent year over year, largely as a result of rapid COVID-19 testing.

GE's healthcare systems organic revenues in the fourth quarter declined 5%, more than offsetting 2% organic growth in pharmaceutical diagnostics. Nonetheless, Culp told investors that healthcare order demand remained strong in the quarter despite supply chain disruptions.

Johnson & Johnson on Tuesday projected that its Covid vaccine would generate $3 billion to $3.5 billion in sales in 2022, after posting a mixed fourth-quarter report that slightly beat on earnings estimates but missed on revenue.

Imagine getting a positive result on a genetic test. The doctor tells you that you have a “pathogenic genetic variant,” or a DNA sequence that is known to raise the chances for getting a disease like breast cancer or diabetes.

Gene editing company Metagenomi said on Tuesday that it has raised $175 million in a Series B financing round, bringing the total funding for the Emeryville, California-based startup to $300 million.

Shenzhen, China, January 24, 2022: Medcaptain Medical Technology and Penlon, a world-renowned medical device manufacturer, formally entered into an acquisition.

Recently, Novogene released the finance forecast that the net profit attributable to owners of the parent company in 2021 was 190 million to 228 million yuan, a year-on-year increase of 419.99% to 523.99%.

Illumina said on Monday that it is collaborating with National Cancer Center Japan on a study of nasopharyngeal carcinoma.

While the Omicron variant continues to infect people around the world, researchers at the University of Missouri have identified the highly prevalent, specific mutations that are causing the Omicron variant’s high rate of infection.

Pancreatic cancer is a rare, yet elusive and deadly cancer, with a five-year survival rate of about 10%. If the cancer has metastasized, that rate lowers to 3%. And treatment options are extremely limited.

Kent, UK-based point-of-care test developer Psyros Diagnostics on Thursday announced it is being acquired by Prolight Diagnostics, based in Lund, Sweden, for SEK 65 million ($7.1 million).

On January 19, Hangzhou Bioer Technology Co., Ltd. signed a strategic cooperation agreement with Dell.

Research from the School of Medicine suggests how a newly developed gene therapy can treat Dravet syndrome, a severe form of epilepsy, and potentially prolong survival for people with the condition.